MTOR and ovarian cancer: The activation of PI3K/Akt/mTOR pathway, which is the most often aberrant signalling pathway discovered in 70 % of ovarian cancer cases, is linked to aggressive phenotypes, chemoresistance, and a poor prognosis, making it an important therapeutic target named PI3K/AKT/mTOR inhibitor [50].